Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Low levels of enhancer of zeste homolog 2 (EZH2) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMathilde Poplineau

Discussion

Loading...

Member takes

Overview

Observation shows poor overall survival in acute myelogenous leukemia with low EZH2 protein, indicating treatment implications for new therapies.

Key Points

  • Low EZH2 protein levels are linked to poor outcomes in acute myelogenous leukemia, even without mutation.
  • Patients with low EZH2 showed reduced overall survival compared to those with high levels in multiple therapies.
  • Assessment using differential expression unveiled similar behavior between patients with low EZH2 and EZH2 mutations.
  • The findings suggest that targeting EZH2 could benefit a larger population of acute myelogenous leukemia patients.

Cite This Study

Mathilde Poplineau (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e046https://doi.org/10.1182/blood-2025-5259
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  2. 2Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  3. 3Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia2025
  4. 4High levels of PTPN11 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  5. 5High protein expression of MDS1 and EVI1 complex locus (MECOM) is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia2025